AAS
MCRB icon

Avantax Advisory Services’s Seres Therapeutics MCRB Stock Holding History

Avantax Advisory Services’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,259
Closed -$31.6K – 2410
2025
Q1 		$31.6K Hold
2,259
– – ﹤0.01% 2211
2024
Q4 		$37.5K Buy
2,259
+1,425
+171% +$23.2K ﹤0.01% 2163
2024
Q3 		$15.8K Hold
834
– – ﹤0.01% 2108
2024
Q2 		$12.1K Buy
+834
New +$13.9K ﹤0.01% 2065

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Avantax Advisory Services's MCRB Position: Q2 2025 in Review

Avantax Advisory Services sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 2,259 shares — an estimated $31.6K sold.

Avantax Advisory Services first reported a position in MCRB in Q2 2024 and held it in 4 quarters. The position peaked at $37.5K in Q4 2024. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Avantax Advisory Services reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Avantax Advisory Services sold 2,259 Seres Therapeutics shares in Q2 2025, an estimated $31.6K.
  • Avantax Advisory Services first reported a position in Seres Therapeutics in Q2 2024 and held it in 4 quarters.
  • Avantax Advisory Services's Seres Therapeutics position peaked at $37.5K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.